Keros Therapeutics 

Quarterly Financials

Values in thousands 2025-06-30 2025-03-31 2024-12-31 2024-09-30
Revenue
$18,168
$211,246
$3,042
$388
Gross Profit
17,798
211,246
2,710
74
EBITDA
-39,817
152,384
-29,142
-58,343
EBIT
-40,187
152,040
-29,474
-58,657
Net Income
-30,696
148,451
-46,026
-52,956
Net Change In Cash
18,168
211,246
3,042
388
Free Cash Flow
-30,343
160,606
-46,297
-30,886
Cash
690,215
720,541
559,931
530,684
Basic Shares
40,612
41,021
40,338
36,103

Annual Financials

Values in thousands 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Revenue
$3,550
$151
$20,000
$20,100
Gross Profit
3,550
-664
-1,615
19,202
EBITDA
-185,824
-152,177
-103,063
-56,373
EBIT
-187,053
-152,992
-104,678
-57,271
Net Income
-187,353
-152,992
-104,680
-58,744
Net Change In Cash
3,550
151
20,000
20,100
Cost of Revenue
49,006
-34,622
Free Cash Flow
-162,800
-126,972
-71,303
-63,172
Cash
559,931
331,147
279,048
230,042
Basic Shares
37,438
29,447
25,241
23,333

Earnings Calls

Quarter EPS
2025-09-30
$0
2025-06-30
-$0.76
2025-03-31
$3.62
2024-12-31
-$1.14